Steven R Feldman

Wake Forest School of Medicine, Winston-Salem, North Carolina, United States

Are you Steven R Feldman?

Claim your profile

Publications (689)1601.43 Total impact

  • A Taheri, P Mansoori, K E Huang, S R Feldman
    [Show abstract] [Hide abstract]
    ABSTRACT: Radiofrequency electrical currents have a tendency to move toward the center of the bulk of biologic tissues.
    Skin Research and Technology 10/2014; · 1.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Atopic dermatitis is a common, chronic inflammatory dermatosis that can affect all age groups. This evidence-based guideline addresses important clinical questions that arise in its management. In this final section, treatments for flare prevention and adjunctive and complementary therapies and approaches are reviewed. Suggestions on use are given based on available evidence.
    Journal of the American Academy of Dermatology 09/2014; · 4.91 Impact Factor
  • JAMA Dermatology 09/2014; · 4.30 Impact Factor
  • Kyle B Bartlett, Scott A Davis, Steven R Feldman
    Journal of the American Academy of Dermatology 09/2014; 71(3):581-582.e2. · 4.91 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Demand for minimally invasive cosmetic procedures have led to an increased market of available products for facial rejuvenation. Objective: To characterize trends in the usage of aesthetic products, specifically the use of botulinum toxins and dermal fillers, by United States physicians. Methods: Data from the National Ambulatory Medical Care Survey was analyzed from 1993 to 2010 to evaluate the use of dermal fillers and neurotoxins in the United States outpatient setting. The types of physician specialties administering these products and their preferences in products were characterized. Results: There were an estimated 100,000 annual cosmetic visits at which a dermal filler was administered from 1993 to 2010. From 2002 to 2010, there were 140,000 annual cosmetic visits for a dermal filler and 440,000 visits for a neurotoxin. While collagen was the most common filler used over the entire study period, its use declined eight percent annually. Hyaluronic acid fillers were preferred from 2002 to 2010, followed by calcium hydroxylapatite filler, representing 50 percent and 16.1 percent of visits, respectively. The leading neurotoxin was onabotulinumtoxin A, used at 87.1 percent of visits. Dermatologists were the leading specialty for the cosmetic use of both dermal fillers and neurotoxins. Conclusion: Providers' preference for cosmetic products appears to be influenced by their familiarity with them, with products that first came to market, such as the neurotoxin onabotulinumtoxin A and the hyaluronic acid fillers being used most frequently from 2002 to 2010.
    Journal of Clinical and Aesthetic Dermatology 09/2014; 7(9):14-19.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patient demographics and operative techniques may contribute to adverse events after surgeries.
    Journal of Cutaneous Medicine and Surgery 09/2014; 18(5):337-40.
  • Farah A Moustafa, Laura F Sandoval, Steven R Feldman
    [Show abstract] [Hide abstract]
    ABSTRACT: Rosacea is a chronic inflammatory skin condition that negatively impacts patients' quality of life. We sought to review important aspects of the pathogenesis of rosacea and the role of new treatment options in its management. New, emerging treatments show promise; however, quality randomized controlled trials for many of these drugs are lacking. Brimonidine tartrate is an effective newly approved treatment for erythematotelangiectatic rosacea. Topical oxymetazoline has potential for the treatment of erythematotelangiectatic rosacea, with efficacy described in case reports and randomized controlled trials currently underway. Both oral and topical ivermectin have been studied for the treatment of papulopustular rosacea, both showing benefit; however, only topical ivermectin 1 % cream has been studied in randomized controlled trials. As our understanding of the etiology of rosacea continues to evolve, so will our options for therapeutic interventions. Further studies need to be performed to assess the long-term safety and efficacy of these treatments.
    Drugs. 08/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract: The treatment of psoriasis has evolved over the years, with the recent focus largely on the use of biologics and anti-interleukin-17 agents. With treatment options expanding, practitioners and patients may find control of psoriasis more convenient and safer to achieve. In this article, we review the literature on emerging medications for the treatment of psoriasis. Although some of the new medications under development, such as the anti-interleukin-17 agents, are being shown to be very efficacious in the treatment of psoriasis in premarketing trials, more information regarding their long-term use is needed to demonstrate their superiority over available modalities.
    psoriasis: targets and therapy. 08/2014; 2014:4.
  • Journal of drugs in dermatology: JDD 08/2014; 13(8):917-20. · 1.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The Center for Dermatology Research is supported by an unrestricted educational grant from Galderma Laboratories, L.P. Dr. Feldman is a consultant and speaker for Galderma, Stiefel/GlaxoSmithKline, Abbott Labs, Warner Chilcott, Janssen, Amgen, Photomedex, Genentech, BiogenIdec, and Bristol Myers Squibb. Dr. Feldman has received grants from Galderma, Astellas, Abbott Labs, Warner Chilcott, Janssen, Amgen, Photomedex, Genentech, BiogenIdec, Coria/Valeant, Pharmaderm, Ortho Pharmaceuticals, Aventis Pharmaceuticals, Roche Dermatology, 3M, Bristol Myers Squibb, Stiefel/GlaxoSmithKline, Novartis, Medicis, Leo, HanAll Pharmaceuticals, Celgene, Basilea, and Anacor and has received stock options from Photomedex. Dr. Feldman is the founder and holds stock in Causa Research. Dr. Sandoval, Ms. Pierce, and Mr. Davis have no conflicts to report.This article is protected by copyright. All rights reserved.
    British Journal of Dermatology 08/2014; · 3.76 Impact Factor
  • Imran Aslam, Laura F Sandoval, Steven R Feldman
    [Show abstract] [Hide abstract]
    ABSTRACT: To review recent literature on the topical treatment of allergic skin diseases to help clinicians make informed evidence-based decisions.
    Current Opinion in Allergy and Clinical Immunology 07/2014; · 3.40 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Costs associated with psoriasis present a considerable economic burden. A previously published review was lacking comprehensive data on biologics. Therefore, a systematic literature review was performed to gain a comprehensive understanding of the economic burden of psoriasis throughout the world. Studies published in the English language between January 2001 and May 2013 reporting the direct and indirect economic burden of psoriasis were identified from PubMed and conference proceedings. Thirty-five studies from 11 countries met the inclusion criteria. In 2004, the annual total cost (direct and indirect) in the USA alone was approximately US$1.40 billion. Among the European countries, the most recent studies reported an annual total cost per patient of €11,928 in Sweden, €8372 in Italy, €2866-6707 in Germany and CDN$7999 in Canada, based on treatment type. Costs associated with psoriasis are high in many countries, indicating a continued need for treatments that offer good value for money.
    Expert Review of Pharmacoeconomics & Outcomes Research 07/2014; · 1.67 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Early follow-up visits improve patient adherence, but the actual scheduling behavior of physicians is not known. PURPOSE: To characterize the timing of first follow-up visits in US dermatologic practice. Methods: Patients with a diagnosis of psoriasis, acne, or atopic dermatitis were identified in the 2003-2007 MarketScan Medicaid database. Factors affecting the length of time before first follow-up were assessed using a Cox proportional hazards model. RESULTS: Mean length of time to the first follow-up visit was 153 days for adults and 142 days for children with psoriasis; 151 days for adults and 218 days for children with acne; and 161 days for adults and 209 days for children with atopic dermatitis. Black and those other than white patients were less likely than whites to receive early follow-up in psoriasis and acne, but more likely in atopic dermatitis. Dermatologists were more likely to schedule early follow-up visits than nondermatologists. LIMITATIONS: The database includes only Medicaid patients. The rate of non-attendance at scheduled visits could not be determined. CONCLUSIONS: Most physicians are missing the opportunity to maximize patient adherence by scheduling early follow-up visits. Contact by email or phone may be beneficial for physicians who cannot schedule early follow-up. J Drugs Dermatol. 2014;13(7):833-836.
    Journal of drugs in dermatology: JDD 07/2014; 13(7):833-836. · 1.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Psoriasis treatment in pregnant women requires weighing the risks to the fetus and benefits to the mother. Little is known about how psoriasis is treated during pregnancy.Objective This study sought to identify the medications most commonly prescribed in pregnant women with psoriasis.Method The Truven 2003-2007 MarketScan™ Medicaid Database was used. Pregnant women with psoriasis were identified by inpatient and outpatient records. The prevalence of drug use was determined by the proportion of prescriptions. Trend of drug use over trimesters was examined using Pearson chi-square tests.Results560 pregnant women with psoriasis who saw a physician before pregnancy were identified, and 386 (68.9%) filled psoriasis drugs. The most common medications prescribed were topical corticosteroids (n=122, 31.6%), with the majority being low to mid-potency (64.8%). The second most common drug category (n=41, 10.6%) used was “other” topical products, including topical vitamin D analogues, pimecrolimus, tacrolimus, urea, salicylic acid, coal tar, topical retinoid, and calcipotriene products. This was followed by biologics (n=2, 0.5%) and other systemic treatments (n=2, 0.5%). Four patients (n=4, 1%) received either methotrexate or tazarotene during their pregnancy- two of which received one of the drugs for the entire gestational period.Conclusions This study revealed the prevalence of medications used in pregnant women with psoriasis, which could provide information in how risks and benefits of treatment in pregnant women were weighed. Prescribing patterns generally were in line with treatment recommendations for pregnant women. However, there were some treatments prescribed that were not suitable for pregnant women.This article is protected by copyright. All rights reserved.
    British Journal of Dermatology 07/2014; · 3.76 Impact Factor
  • Farah Moustafa, Robin S Lewallen, Steven R Feldman
    [Show abstract] [Hide abstract]
    ABSTRACT: Rosacea is a common problem that is underdiagnosed; if left untreated can result in physical disfigurement and emotional distress.
    Journal of the American Academy of Dermatology 06/2014; · 4.91 Impact Factor
  • Scott A Davis, Steven R Feldman, Sarah L Taylor
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Objectives: The objective of this study was to assess how often St. John's wort (SJW) is prescribed with medications that may interact dangerously with it. Design: The study design was a retrospective analysis of nationally representative data from the National Ambulatory Medical Care Survey. Settings: The study setting was U.S. nonfederal outpatient physician offices. Subjects: Those prescribed SJW between 1993 and 2010 were the subjects. Outcome Measures: The outcome measures were medications co-prescribed with SJW. Results: Twenty-eight percent (28%) of SJW visits involved a drug that has potentially dangerous interaction with SJW. These included selective serotonin reuptake inhibitors, benzodiazepines, warfarin, statins, verapamil, digoxin, and oral contraceptives. Conclusions: SJW is frequently used in potentially dangerous combinations. Physicians should be aware of these common interactions and warn patients appropriately.
    Journal of alternative and complementary medicine (New York, N.Y.) 06/2014; · 1.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acne is occurring more frequently in younger age groups, but most available treatments are considered off-label in young children. As the epidemiology of acne has changed to include younger children over the past 20 years, neither regulators, pharmaceutical companies, nor clinicians have understood the need or value of obtaining regulatory sanctions for problems physicians have managed using clinical judgment. The objective of this study was to analyze the frequency of off-label acne treatment according to age and other demographic factors. We searched the National Ambulatory Medical Care Survey from 1993 to 2010 for visits in children younger than 12 years of age for the diagnosis of International Classification of Diseases, Ninth Revision, code 706.1. We tabulated leading acne treatments and assessed factors associated with off-label prescribing. Off-label but appropriate acne treatments were used in 29% of acne visits for children younger than 12 years of age. Dermatologists were more likely than pediatricians to prescribe off-label treatment (p < 0.001). The most frequently used off-label treatments were topical retinoids, followed by oral antibiotics. There was no significant trend in the rate of off-label prescribing over time (p = 0.40). Off-label treatment is well within the standard of care for young children with acne. More data on the use of topical retinoids in young children will improve our understanding of their use, which may help optimize treatment outcomes for children with acne.
    Pediatric Dermatology 06/2014; · 1.04 Impact Factor
  • Hossein Alinia, Steven R Feldman
    JAMA Dermatology 06/2014; · 4.30 Impact Factor
  • Steven R Feldman, William W Huang, Tu T Huynh
    Journal of managed care pharmacy: JMCP 06/2014; 20(6):623-9. · 2.41 Impact Factor
  • Karen E Huang, S Evan Carstensen, Steven R Feldman
    [Show abstract] [Hide abstract]
    ABSTRACT: Acne has a ~90% lifetime prevalence, however the duration of the condition and its treatment is not well characterized. The purpose of this study was to estimate for how long acne patients are treated. METHODS: Electronic patient records from an academic practice were queried to identify dermatology visits with an acne diagnosis (ICD-9: 706.1) between January 1, 2009 and June 1, 2012. The duration of care for acne treatment was calculated as the time between the earliest and latest visits. Kaplan Meier analyses were used to describe treatment duration. RESULTS: 1,130 patients had at least one visit acne-related visit to a dermatologist, with 631 (56%) having only one visit and 499 (44%) having multiple visits over the study period. For patients with multiple visits, the mean duration from first to last visit was 0.57 year (95% CI: 0.52, 0.62); 25% ceased visiting in 0.25 year, 50% in 0.40 year, and 75% in 0.64 year. CONCLUSION: Our study provides a lower limit on the duration of acne treatment. The duration of acne treatment is longer than the duration of typical acne clinical trials. Understanding the duration of the disease can help set patients' treatment expectations, which may help improve adherence. J Drugs Dermatol. 2014;13(6):655-656.
    Journal of drugs in dermatology: JDD 06/2014; 13(6):655-656. · 1.16 Impact Factor

Publication Stats

8k Citations
1,601.43 Total Impact Points

Institutions

  • 1994–2014
    • Wake Forest School of Medicine
      • • Department of Dermatology
      • • Division of Public Health Sciences
      Winston-Salem, North Carolina, United States
  • 1992–2014
    • Wake Forest University
      • • School of Medicine
      • • Department of Dermatology
      • • Department of Psychology
      Winston-Salem, North Carolina, United States
  • 2013
    • Rady Children's Hospital
      San Diego, California, United States
  • 2009–2013
    • University of Michigan
      • Department of Clinical, Social, and Administrative Sciences
      Ann Arbor, MI, United States
    • University of Maryland, Baltimore
      Baltimore, Maryland, United States
    • Wright State University
      Dayton, Ohio, United States
    • Johns Hopkins University
      Baltimore, Maryland, United States
    • Yale University
      New Haven, Connecticut, United States
    • Columbus State University
      Columbus, Georgia, United States
  • 2012
    • University of Southern California
      • Keck School of Medicine
      Los Angeles, California, United States
    • University of South Florida
      • Department of Dermatology and Cutaneous Surgery
      Tampa, FL, United States
  • 2011
    • University of North Carolina at Chapel Hill
      North Carolina, United States
    • Washington University in St. Louis
      • Division of Dermatology
      Saint Louis, MO, United States
    • University of Georgia
      • Department of Clinical and Administrative Pharmacy
      Athens, GA, United States
    • University of Chicago
      • Section of Dermatology
      Chicago, IL, United States
  • 2008–2011
    • Baylor Health Care System
      Dallas, Texas, United States
    • Harvard Medical School
      • Department of Dermatology
      Boston, MA, United States
    • University of Massachusetts Medical School
      Worcester, Massachusetts, United States
    • Geisel School of Medicine at Dartmouth
      Hanover, New Hampshire, United States
  • 2010
    • University of Notre Dame
      • College of Science
      Indiana, PA, United States
    • Wayne State University
      • Department of Dermatology
      Detroit, MI, United States
  • 2009–2010
    • University of California, Davis
      • School of Medicine
      Davis, CA, United States
    • State University of New York Upstate Medical University
      Syracuse, New York, United States
  • 2005–2009
    • The Ohio State University
      • Division of Pharmacy Practice and Administration
      Columbus, OH, United States
    • Loyola University Medical Center
      Maywood, Illinois, United States
    • Cincinnati Museum Center
      Cincinnati, Ohio, United States
    • Johns Hopkins Medicine
      Baltimore, Maryland, United States
    • University of Pennsylvania
      • Department of Dermatology
      Philadelphia, PA, United States
  • 2004–2009
    • University of North Carolina at Greensboro
      • • Department of Public Health Education
      • • Department of Psychology
      Greensboro, North Carolina, United States
    • University of Toronto
      • Department of Medicine
      Toronto, Ontario, Canada
    • Kent State University
      • Department of Geography
      Kent, Ohio, United States
    • Beth Israel Deaconess Medical Center
      • Department of Dermatology
      Boston, MA, United States
  • 2007
    • Ohio University
      Athens, Ohio, United States
  • 2006–2007
    • Northeast Ohio Medical University
      Ravenna, Ohio, United States
    • George Washington University
      Washington, Washington, D.C., United States
    • Medical University of South Carolina
      • Division of General Internal Medicine and Geriatrics
      Charleston, SC, United States
  • 2004–2005
    • University of Texas Health Science Center at Houston
      • • School of Public Health
      • • Division of Management, Policy and Community Health
      Houston, TX, United States
  • 2003–2004
    • Mount Sinai School of Medicine
      • Department of Dermatology
      Manhattan, NY, United States
  • 2002
    • Mount Sinai Medical Center
      New York City, New York, United States
    • Sunnybrook Health Sciences Centre
      • Department of Medicine
      Toronto, Ontario, Canada
    • Bristol-Myers Squibb
      New York City, New York, United States
  • 2001
    • Georgetown University
      Washington, Washington, D.C., United States
  • 1997–1999
    • Winston-Salem State University
      Winston-Salem, North Carolina, United States
    • University of Milan
      • Department of Pharmacological Sciences
      Milano, Lombardy, Italy